Investment
Features
FeesSafety
Academy
More
Pluang+

Compare NeoGenomics Inc. Common Stock (NEO) vs GeneDx Holdings Corp (WGS) Price & Performance

NeoGenomics Inc. Common StockTrade
GeneDx Holdings CorpTrade

Price performance (Past 24H)

Key statistics

NeoGenomics Inc. Common Stock vs GeneDx Holdings Corp — how do they compare? NeoGenomics Inc. Common Stock trades at $16.85 (market cap $2.14B), while GeneDx Holdings Corp trades at $68.8 (market cap $1.94B). The key difference: NeoGenomics Inc. Common Stock and GeneDx Holdings Corp are close in size by market cap, and NeoGenomics Inc. Common Stock is trading nearer its 52-week high, GeneDx Holdings Corp nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold NeoGenomics Inc. Common Stock for 0 Days and GeneDx Holdings Corp for 20 Days on average.

NEOWGS
Market Cap
$2.14B$1.94B
Volume
2,228,400524,385
Sector
HealthHealth
52-Week High
$19.91$167.51
52-Week Low
$7.19$34.51
Typical Hold Time
0 Days20 Days
Enterprise Value
$2.44B$1.97B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

NeoGenomics Inc. Common Stock

No Aura AI signal available yet.

GeneDx Holdings Corp

GeneDx (WGS) trades at $64.96, up 1.79% today, showing mixed signals with bearish technical indicators but strong analyst support. The company reported Q2 2026 revenue of $114.4 million, beating expectations with record testing volumes, though profitability remains challenged with negative net margins. Recent news highlights product innovations and leadership recognition, while institutional interest grows with Dimensional Fund Advisors increasing its position by 143.4% in Q1 2026.

The stock presents a high-risk opportunity with 91% analyst buy ratings and an $81 consensus target offering 25% upside. However, significant fundamental challenges include negative profitability, high valuation multiples, and cash flow volatility. Investors should weigh strong growth potential in genomic testing against execution risks and competitive pressures in the healthcare technology sector.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

NEO
100% Buy0% Sell
Avg holding period · 0 Days
WGS
100% Buy0% Sell
Avg holding period · 20 Days

About NeoGenomics Inc. Common Stock

NeoGenomics, Inc. is a US cancer diagnostics company that provides genomic and pathology testing services, offering an oncology-focused testing menu used by oncologists, pathologists, and hospital systems across the cancer care continuum.

Read more on NEO →

About GeneDx Holdings Corp

GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.

Read more on WGS →